posted on 2023-03-31, 03:46authored byNinghui Mao, Dong Gao, Wenhuo Hu, Sunyana Gadal, Haley Hieronymus, Shangqian Wang, Young Sun Lee, Patrick Sullivan, Zeda Zhang, Danielle Choi, Neal Rosen, Charles L. Sawyers, Anuradha Gopalan, Yu Chen, Brett S. Carver
The supplementary figures provide additional data demonstrating that ERG represses RTK-PI3K signaling through direct transcriptional repression of IRS2 across multiple model systems. Additional data is provided showing the biologic role of ERG and PI3K signaling in promoting cell proliferation and migration.
Funding
NIH
NCI
PCF
MSKCC
Howard Hughes Medical Institute
STARR Cancer Consortium
History
ARTICLE ABSTRACT
Genomic rearrangements leading to the aberrant expression of ERG are the most common early events in prostate cancer and are significantly enriched for the concomitant loss of PTEN. Genetically engineered mouse models reveal that ERG overexpression alone is not sufficient to induce tumorigenesis, but combined loss of PTEN results in an aggressive invasive phenotype. Here, we show that oncogenic ERG repressed PI3K signaling through direct transcriptional suppression of IRS2, leading to reduced RTK levels and activity. In accordance with this finding, ERG-positive human prostate cancers had a repressed AKT gene signature and transcriptional downregulation of IRS2. Although overexpression of IRS2 activated PI3K signaling, promoting cell migration in a PI3K-dependent manner, this did not fully recapitulate the phenotype seen with loss of PTEN as PI3K signaling is not as robust as observed in the setting of loss of PTEN. Importantly, deletions of the PTEN locus, which promotes active PI3K signaling, were among the most significant copy-number alterations that co-occurred with ERG genomic rearrangements. This work provides insight on how initiating oncogenic events may directly influence the selection of secondary concomitant alterations to promote oncogenic signaling during tumor evolution.
This work provides insight on how initiating oncogenic events may directly influence the selection of secondary concomitant alterations to promote tumorigenesis.